Group 1 - The core viewpoint of the article is that Changjiang Life Science Technology (00775) issued a profit warning, leading to a decline of over 5% in its stock price, currently trading at HKD 0.95 with a transaction volume of HKD 5.7489 million [1] - The company anticipates a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a profit of HKD 1 million in the same period of 2024 [1] - The shift from profit to loss is attributed to the company's earlier decision to increase research and development investments [1] Group 2 - Overall, the company's operations have remained stable during the reporting period and up to the date of the announcement [1]

Core Viewpoint - Changjiang Life Science Technology (00775) issued a profit warning, leading to a decline of over 5% in its stock price, currently trading at HKD 0.95 with a trading volume of HKD 5.7489 million [1] Financial Performance - The company expects to report a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a shareholder profit of HKD 1 million for the same period in 2024 [1] - The shift from profit to loss is attributed to the company's earlier decision to increase research and development investments [1] Operational Stability - Overall, the company's operations have remained stable during the reporting period and up to the date of the announcement [1]

Performance Updates - 开拓药业-B (09939.HK) has completed patient enrollment for the Phase III clinical trial of KX-826 solution for androgenetic alopecia in adult males in China [2] - 李氏大药厂 (00950.HK) has received approval from the National Medical Products Administration for Socazolimab to be used in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer in mainland China [2] - 恒瑞医药 (01276.HK) has received approval for clinical trials of SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [2] - 恒瑞医药 (01276.HK) has also received approval to conduct clinical trials for HRS-5041, intended for prostate cancer treatment [2] - 深圳高速公路股份 (00548.HK) reported toll revenue of 106 million yuan for the outer ring project in June [2] - 大成生化科技 (00809.HK) has signed an EPC contract with Northeast Electric and Liaoning Electric for boiler renovation projects, with a maximum cost of 129.1 million yuan [2] - 小黄鸭德盈 (02250.HK) has signed a contract to develop an AI marketing system to diversify revenue sources [2] Buyback and Financing Activities - 威海银行 (09677.HK) plans to issue up to approximately 758 million domestic shares and 154 million H-shares, raising nearly 3 billion yuan [2] Financial Results - 香港电讯-SS (06823.HK) reported total revenue of 17.322 billion HKD for the first half, a year-on-year increase of 4%, with a net profit of 2.07 billion HKD, also up 4% [4] - 青岛银行 (03866.HK) reported operating revenue of 7.662 billion yuan for the first half, a growth of 7.5%, and a net profit of 3.065 billion yuan, up 16.05% [4] - 中国石油化工股份 (00386.HK) expects mid-term net profit to be between 20.1 billion and 21.6 billion yuan, a year-on-year decline of 39.5%-43.7% [4] - 汽车之家-S (02518.HK) reported total revenue of 3.212 billion yuan for the first half, a decrease of 7.75%, with a net profit of 772 million yuan, down 15.99% [4] - 绿茶集团 (06831.HK) issued a profit warning, expecting mid-term net profit to be between 230 million and 237 million yuan, a year-on-year increase of approximately 32%-36% [4] - 粤海置地 (00124.HK) issued a profit warning, expecting mid-term net profit to exceed 260 million HKD, turning from loss to profit [4] - 药师帮 (09885.HK) issued a profit warning, expecting mid-term net profit to exceed 70 million yuan [4] - 中国东方教育 (00667.HK) issued a profit warning, expecting mid-term net profit to grow by 45%-50% year-on-year [4] - 中核国际 (02302.HK) issued a profit warning, expecting mid-term revenue to increase to at least 585 million HKD, with net profit of at least 9.5 million HKD [4] - 大唐环境 (01272.HK) issued a profit warning, expecting mid-term net profit to decrease to between 350 million and 400 million yuan [4] - 长江生命科技 (00775.HK) issued a profit warning, expecting mid-term net loss of approximately 150 million HKD, turning from profit to loss year-on-year [4] - 延长石油国际 (00346.HK) issued a profit warning, expecting mid-term loss of approximately 27.9 million HKD [4]

Core Viewpoint - Changjiang Life Science Technology (00775) expects to report a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a profit of HKD 1 million in the same period of 2024, primarily due to the company's decision to increase R&D investment [1] Group 1 - The expected shareholder loss of HKD 150 million marks a significant shift from the previous year's profit of HKD 1 million [1] - The company's operational performance has remained stable during the reporting period and up to the date of this announcement [1]

Core Viewpoint - Changjiang Life Science Technology (00775) expects to report a shareholder loss of approximately HKD 150 million for the six months ending June 30, 2025, compared to a profit of HKD 1 million in the same period of 2024, primarily due to the company's decision to increase R&D investment [1] Group 1 - The company anticipates a significant shift from profit to loss in its financial performance [1] - The expected loss is attributed to increased investments in research and development [1] - Overall, the company's operations have remained stable during the reporting period and up to the date of the announcement [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：0775） 盈利警告 本公告乃根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09(2)(a)條及證券 及期貨條例（香港法例第 571 章）第 XIVA 部項下之內幕消息條文（定義見上市規則）刊發。 長江生命科技集團有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董事會（「董 事會」）謹此通知本公司股東（「股東」），根據本集團截至二零二五年六月三十日止六個月 （「報告期間」）未經審核綜合管理賬目（「管理賬目」）之初步審閱，以及董事會目前所得之 資料，本集團預期報告期間錄得約港幣一億五千萬元股東應佔虧損，對比二零二四年同期，股東 應佔溢利為港幣一百萬元。是次應佔溢利轉盈為虧乃歸因於本公司早前計劃增加研發投資之決定。 整體而言，本集團的營運於報告期間及截至本公告日期一直維持穩定。本公司將於二零二五年 八月十二日發佈之中期業績公告中披露更多詳 ...

格隆汇7月31日丨长江生命科技(00775.HK)宣布，公司将于2025年8月12日（星期二）于香港举行董事会 会议，以（其中包括）批准刊发公司及其附属公司截至2025年6月30日止六个月的中期业绩，以及考虑 派发中期股息。 ...

(於開曼群島註冊成立之有限公司) （股份代號：0775） 董事會召開日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本文件的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本文件全部或任何部分 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 香港，二零二五年七月三十一日 於本文件日期，本公司執行董事為李澤鉅先生（主席）、甘慶林先生、葉德銓先生、 余英才先生 、 Lance Richard Lee Yuen 先 生 及 杜 健 明 醫 生 ； 非 執 行 董 事 為 Peter Peace Tulloch 先生、郭李綺華女士（獨立非執行董事）、關啟昌先生（獨立非執行 董事）、Paul Joseph Tighe 先生（獨立非執行董事）及羅弼士先生（獨立非執行董事）。 長江生命科技集團有限公司（「本公司」）之董事會（「董事會」）謹此宣佈，本公司將於 二零二五年八月十二日（星期二）於香港舉行董事會會議，以（其中包括）批准刊發本公司及 其附屬公司截至二零二五年六月三十日止六個月之中期業績，以及考慮派發中期股息。 承董事會命 長江生命科技集團有限公司 公司秘書 楊逸芝 ...

Core Viewpoint - The biotechnology sector is characterized by high returns and high risks, with successful products potentially surpassing the value of many listed infrastructure and real estate companies [1] Group 1: Company Strategy and Research - The company is currently engaged in multiple cancer vaccine research projects, including the TROP2 cancer vaccine, which has shown significant tumor growth inhibition in preclinical studies [1] - The TROP2 protein is overexpressed in various cancers, including triple-negative breast cancer, lung cancer, and colorectal cancer, with the company's vaccine demonstrating 100% tumor growth inhibition in mouse models [1] - The company estimates that it will take approximately 24-30 months to initiate Phase I/II clinical trials for the TROP2 vaccine [1] Group 2: Asset Management and Financial Strategy - The company considers its health products and agriculture-related businesses as important, generating stable cash flow to support research and development [1] - The company will continue to evaluate strategic options to enhance shareholder value and optimize its business structure, with any significant developments to be disclosed to the market [1] - There are currently no announcements regarding the potential spin-off of the biopharmaceutical division for a Hong Kong listing, and the company is assessing strategic opportunities to improve shareholder value [2] - The company has not announced any plans for fundraising through share placements or convertible bonds to support research and development [2]

Group 1 - Jiangsu Life Science Technology (00775.HK) recently announced promising early results from preclinical laboratory tests of its novel cancer vaccine targeting trophoblast cell surface antigen 2 (TROP2) [1] - The TROP2 vaccine has shown significant tumor growth inhibition in preclinical studies, with four out of five studies demonstrating 100% tumor growth suppression and one study showing approximately 80% suppression in over 170 mice [1] - The TROP2 vaccine is expected to become the first curative therapy for high-incidence cancers in Asia, addressing urgent clinical needs and potentially covering multiple cancer types such as lung and pancreatic cancer [1] Group 2 - The company has multiple clinical-stage medical research projects and its R&D product line is considered severely undervalued, with potential for value release and substantial performance contributions [2] - The company reported a nearly 60% year-on-year increase in clinical trial and laboratory expenses, reaching HKD 161 million in 2024, indicating a strong commitment to R&D [2] - The company is exploring various strategic options, including strategic partnerships, joint ventures, business spin-offs, and mergers, to maximize shareholder value and enhance its capital acquisition channels [2]